Hydroxychloroquine (HCQ) showed no clear difference in death due to any cause compared with standard care or placebo (high certainty).
Hydroxychloroquine (HCQ) probably leads to higher participants with any adverse events compared with placebo (moderate certainty).
Hydroxychloroquine (HCQ) showed no clear difference in negative PCR for SARS‐CoV‐2 on respiratory samples at day 14 from… compared with standard care or placebo (low certainty).
Hydroxychloroquine (HCQ) showed no clear difference in progression to mechanical ventilation compared with standard care or placebo (moderate certainty).
It is very uncertain whether hydroxychloroquine (HCQ) changes time to clinical improvement compared with standard care or placebo (very low certainty).
Hydroxychloroquine (HCQ) probably leads to higher participants with any adverse events compared with standard care or placebo (moderate certainty).
Hydroxychloroquine (HCQ) showed no clear difference in participants with serious adverse events compared with standard care or placebo (low certainty).
It is very uncertain whether hydroxychloroquine (HCQ) changes participants with prolongation of QT‐interval on ECG compared with standard care or placebo (very low certainty).
It is very uncertain whether hydroxychloroquine (HCQ) changes development of confirmed COVID‐19 at 14 days from enrolment compared with placebo (very low certainty).
It is very uncertain whether hydroxychloroquine (HCQ) changes hospitalized due to COVID‐19c compared with placebo (very low certainty).